Kaerus Bioscience

Activities: Research & Development Digital

Trending Articles

  1. Loftware and RiseNow partner to strengthen supply chain traceability and compliance in healthcare settings The alliance pairs Loftware's SAP-integrated product identification platform with RiseNow's procurement and supply chain advisory services, delivering end-to-end...
  2. AlzeCure receives $12m upfront as NeuroRestore Alzheimer's platform licensing deal with QuantumCell closes The payment — comprising $7m in licence fees and $5m direct investment — kicks off a collaboration worth more than $2.2bn in potential milestones, with QuantumCell assuming...
  3. FairJourney Bio engineers tumour-conditional IL-12 switch to improve therapeutic window The company has engineered a dual-specificity antibody fragment designed to activate IL-12 selectively in the tumour microenvironment, with preclinical data and quantitative...
  4. Syntegon launches pilot-scale tablet coater for flexible OSD manufacturing The new Sepion 75 tablet coater is designed to support flexible batch processing, containment of highly potent APIs and direct scale-up from pilot to commercial production
  5. SCHOTT Pharma advances climate action with updated science-based climate targets Updated Scope 3 emissions target strengthens focus on measurably reducing emissions across the value chain

Upcoming event

CPhI Milan

6–8 October 2026 | Exhibition | Fiera Milano, Italy See all

Related Content

Research & Development
Servier acquires potential treatment for Fragile X syndrome

Servier acquires potential treatment for Fragile X syndrome

KER-0193, a novel, orally bioavailable small molecule, was granted orphan drug and rare paediatric drug designation by the US FDA
Research & Development
Neurolentech partners with Kaerus Bioscience to advance neurodevelopmental disorder research

Neurolentech partners with Kaerus Bioscience to advance neurodevelopmental disorder research

Kaerus Bioscience will access Neurolentech’s NDD Drug Discovery Platform to support development of its preclinical asset pipeline for numerous genetic syndromes
Subscribe now